The authors reported an association of SSTR2 expression with SDHB/SDHx mutations and metastatic disease, and confirmed a high disease control rate of somatostatin receptor-based therapies in metastatic PPGLs [129,130]. Here, SSTR2 is linked to metastatic neoplasm.